TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $75.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).

The analyst commented: "BHV-1300 Is Crushing Its Target With Record >80% IgG Reductions & Strong Safety; Biohaven shared updated BHV-1300 data demonstrating 80-84% IgG reduction following Q1W dosing of 1000mg over 4 weeks. This is a sizable jump from the Vyvgart-like efficacy (>60%) seen at the lowest dose, and future updates at higher doses could prove even more impressive. The company plans to initiate a PhII in Graves' mid-year, with potential rapid achievement of clinical POC via biomarkers."

For an analyst ratings summary and ratings history on Biohaven Pharmaceutical Holding click here. For more ratings news on Biohaven Pharmaceutical Holding click here.

Shares of Biohaven Pharmaceutical Holding closed at $32.06 yesterday.